COVID-19 therapy with neutralising monoclonal antibodies

Author(s): Erica Bronen

Several neutralising monoclonal Antibodies (mAbs) to the coronavirus that causes Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) have been produced and are currently being tested in clinical trials. Given the recent emergency use authorizations for neutralising mAbs in non-hospitalized patients with mild-to-moderate COVID-19 by the US Food and Drug Administration, there is an urgent need to discuss the broader potential of these novel therapies and develop strategies to effectively deploy them in clinical practise, given their limited initial availability. From the history of passive vaccination and the lessons learnt from employing antibody treatments to treat viral illnesses including respiratory syncytial virus, Ebola virus, and SARS-CoV. The use of convalescent plasma and neutralising mAbs for SARS-CoV-2 treatment is then discussed. For optimal clinical application, examine particular clinical problems such as the rationale for patient categorization, prospective biomarkers, known risk factors, and temporal considerations. To answer these questions, researchers must first comprehend factors such as viral load kinetics and their relationship to clinical outcomes, endogenous antibody responses, neutralising mAb pharmacokinetic properties, and the potential benefit of combining antibodies to defend against emerging viral variants.